Return on investment for research and development costs in the pharmaceutical industry is at its lowest level since 2010, according to Deloitte's 10th annual ROI of R&D report, released Dec. 18.
By looking at data from the top 12 global pharmaceutical companies, collected by Deloitte's Centre for Health Solutions, the study found that projected return on investment for research and development was 1.8 percent in 2019, the lowest level since the company began tracking the numbers in 2010, when ROI was at 10.1 percent. It's a slight fall from last year, when the number was 1.9 percent.
